Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations].

Bulletin du cancer - 1 Oct 2014

Hofman Véronique, Ilie Marius, Long Elodie, Lassalle Sandra, Butori Catherine, Bence Coraline, Washetine Kevin, Lalvee Salomé, Hofman Paul

Abstract excerpt

The concept of personalized or stratified medicine in thoracic oncology have led to the development of companion diagnostic testing in the laboratories in order to detect genomic alterations which can be targeted by therapeutic molecules. The use of these companion tests has to be associated with an optimized quality control with the aim of getting solid results before treatment administration to the patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to MET gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ROS1 gene

Share to Immunohistochemistry

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 25373695
DOI: 10.1684/bdc.2014.2041

Genes

ALK
BRAF
EGFR
MET
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations].PMID 25373695Read ↗

[Molecular pathology of lung cancer in routine diagnostic practice: 2017 update].Semantic proximity Read ↗

[Molecular pathology of pulmonary carcinomas].Semantic proximity Read ↗

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?Semantic proximity Read ↗

Molecular testing and personalized treatment of lung cancer.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

[Molecular diagnostics of lung cancer].Semantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Molecular Testing of Lung CancersSemantic proximity Read ↗

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.